• The most significant advances in cancer treatment start with a deep understanding of cancer biology; yet, even these biologically-driven hypotheses must be empirically validated given the complexity of the human body. This is why today immunotherapy treatments, which harness the power of our own immune systems, or …

    Continue Reading

  • Recognizing Value Through Collaboration

    As adoption of comprehensive genomic profiling (CGP) becomes more widespread in cancer treatment, new research is redefining the clinical utility of diagnostic tests in this age of precision medicine. The value of CGP lies in helping to inform decisions on available treatment options, including clinical trial …

    Continue Reading

  • Measuring the Value of Matched Therapy

    Broad molecular tumor profiling can offer clinical benefits to many cancer patients. This is further supported by the addition of broad genomic profiling to oncology practice guidelines, like the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in melanoma and non-small cell lung cancer (NSCLC). Now, …

    Continue Reading

  • Shifting the Treatment Paradigm in Blood Cancers: New Insights

    For decades, the approach to treating diseases like acute leukemia, lymphoma, and myeloma was based on assigning patients to prognostic groups and making uniform treatment decisions within that group. But with comprehensive genomic profiling, we can begin to unravel the heterogeneity within each group and develop more …

    Continue Reading

  • Personalized: Lung cancer’s present offers a glimpse at cancer’s future

    The impact of precision medicine on cancer treatment becomes more apparent each day. If you consider the patient experience, you start to see how much has changed already — and how much more is possible. When I began caring for patients with non-small cell lung cancer (NSCLC) about 30 years ago, the major therapeutic …

    Continue Reading

  • Expanding options for more patients: Introducing FoundationOne®Liquid

    With a single tissue biopsy and comprehensive genomic profiling (CGP), people diagnosed with cancer have access to more information about their disease than ever before. These insights are rapidly advancing precision medicine and giving patients the chance to find the treatment most likely to benefit their specific …

    Continue Reading

  • Setting the Pace for Blood Tumor Mutational Burden

    New biomarkers for cancer immunotherapy have taken center stage at major oncology meetings recently, mostly notably the genomic biomarker tumor mutational burden (TMB). Multiple clinical trial results support TMB’s potential in identifying patients most likely to benefit from immunotherapy across a wide range of tumor …

    Continue Reading

  • Approximately 15 percent of all colorectal cancers (CRCs) are genetically defined as microsatellite instability (MSI) high.1 This means that the DNA repair mechanisms in the tumor cells are faulty, and as a result, they can acquire a significant number of mutations that can make them easily recognizable by the immune …

    Continue Reading

  • Quantum Leaps for Quantitative Markers

    Recent clinical data demonstrate the enormous impact that quantitative genomic biomarkers like tumor mutational burden (TMB) have made on the treatment landscape, especially in immunotherapy. TMB was a major topic at the recent American Association for Cancer Research (AACR) Annual Meeting, standing alongside data …

    Continue Reading

  • The Future of Personalized Cancer Care is Now

    Cancer immunotherapy has revolutionized how we view cancer treatment. When it works, the results are transformative. But right now, only a subset of people treated with immunotherapies respond. The ability to reliably identify both responders and non-responders to immunotherapy is one of the most important …

    Continue Reading